Cellectis S.A. (CLLS) Fair Value 2026

CLLS · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.9 /10

32 fundamental signals · 11 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Cellectis S.A. (CLLS) trades at $2.81, approximately 568% above CirclFi’s Bayesian DCF fair value of $0.42. QOC: 2.9/10. 11/13 models active.

Key Facts

Ticker
CLLS
Price
$2.81
Quality Score
2.9/10
Value Trap Risk
—/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +79.7% upside with 11% confidence
Risk: Below-average Quality Score of 2.9/10 signals weak fundamentals

Is Cellectis S.A. (CLLS) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Cellectis S.A. (CLLS) appears overvalued as of : the median of 11 independent fair value estimates is $1.97, 29.9% below the current price of $2.81. Estimates range from $0.10 to $5.05. CLLS scores 2.9/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Cellectis S.A. Stock in 2026? →

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($2.81)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.42 -85.0%
Earnings Power Value
Medium Conviction
 $1.52 -45.9%
CUCE Ensemble
Low Conviction
 $1.97 -29.9%
First Chicago
Low Conviction
 $5.05 +79.7%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is Cellectis S.A. (CLLS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Cellectis S.A.'s intrinsic value is estimated at a composite fair value of $2.20. Trading at $2.81, the stock is approaching fair value or slight overvaluation (implied return of -21.5%), as 7 of 11 models suggest limited further upside. Model dispersion is worth noting: First Chicago targets $5.05 (+79.7%), versus ML-RIV at $0.10 (-96.4%). This +176.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About CLLS?

11 of 13 models are currently active for CLLS. Of these, 4 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates CLLS's intrinsic value at $0.42, implying -85.0% downside from the current price. See which stocks rank higher →

How Does CLLS Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, CLLS ranks #127 by Quality of Company score. CirclFi's QOC score of 2.9/10 evaluates 32 fundamental signals. A score of 2.9 signals below-average fundamentals.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Cellectis S.A. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is CLLS a Value Trap?

The Value Trap algorithm is not active for CLLS. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Cellectis S.A.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Cellectis S.A. earns a quality score of 2.9/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +176.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CLLS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CLLS's 11 active models, average confidence is 16%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cellectis S.A. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Cellectis S.A.

What is Cellectis S.A.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Cellectis S.A. (CLLS) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.42. The Quality of Company score is 2.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CLLS overvalued or undervalued right now?

At $2.81, 4 of 11 active models suggest CLLS may be undervalued, while 7 indicate potential overvaluation. The median of all 11 fair value estimates is $1.97, 29.9% below the current price of $2.81 — a consensus view that CLLS is overvalued. The assessment depends on which methodology best fits Cellectis S.A.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 2.9 mean for CLLS?

Cellectis S.A.'s QOC of 2.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CLLS?

CirclFi analyzes CLLS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is CLLS a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for CLLS at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Cellectis S.A. (CLLS) has a median fair value of $1.97 — 29.9% below the current price of $2.81 — as of 2026-07-15.” Source: circlfi.com/stock/CLLS/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on CLLS.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access